DURAGESIC-75
LOE ApproachingNDATRANSDERMALFILM, EXTENDED RELEASE
Approved
Aug 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DURAGESIC-75 is a transdermal extended-release film formulation approved in 1990 for chronic pain management. The product delivers consistent dosing through the skin over an extended period, providing an alternative to oral or injectable pain therapies. Specific indications and mechanism of action are not disclosed in available data.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30); expect brand team restructuring and shift toward lifecycle management or transition roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on DURAGESIC-75 offers limited growth trajectory as the product approaches loss of exclusivity, making it suitable for consolidation, maintenance, or transition roles. Career advancement may depend on success in generic transition management or lateral movement to growth-stage assets within the Johnson & Johnson portfolio.
Brand ManagerField Sales Representative
Worked on DURAGESIC-75 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.